Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia

Onset of progression even during therapy with novel drugs remains an issue in chronic lymphocytic leukemia (CLL). Thus, there is ongoing demand for novel agents. Approaches targeting cyclin-dependent kinases (CDK) have reached the clinical trial stage. CDK9 mediating RNA transcriptional elongation i...

Descripción completa

Detalles Bibliográficos
Autores principales: Göthert, Joachim R., Imsak, Roze, Möllmann, Michael, Kesper, Stefanie, Göbel, Maria, Dührsen, Ulrich, Scholz, Arne, Lücking, Ulrich, Baumann, Matthias, Unger, Anke, Schultz-Fademrecht, Carsten, Klebl, Bert, Eickhoff, Jan, Choidas, Axel, Dürig, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995184/
https://www.ncbi.nlm.nih.gov/pubmed/29899864
http://dx.doi.org/10.18632/oncotarget.25293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995184/
https://www.ncbi.nlm.nih.gov/pubmed/29899864
http://dx.doi.org/10.18632/oncotarget.25293

Ejemplares similares